The New York attorney general has begun an inquiry into Turing Pharmaceuticals, whose fiftyfold overnight increase in the price of a 62-year-old infection drug stoked a backlash against high pharmaceutical prices. 
 
 The attorney general’s office is looking not so much at the price increase itself but at whether Turing may have violated antitrust rules by restricting distribution of the drug, Daraprim, as a way to thwart generic competition, according to a letter sent by the attorney general’s office to Turing on Monday. 
 
 “While competition might ordinarily be expected to deter such a massive price increase, it appears that Turing may have taken steps to prevent that competition from arising,” said the letter, a copy of which was obtained by The New York Times. 
 
 The letter was addressed to Martin Shkreli, the 32-year-old former hedge fund manager who runs Turing, and was signed by Eric J. Stock, the chief of the antitrust bureau. It asks that Turing contact the attorney general’s office immediately to discuss the situation and tells the company to “retain all documents that are potentially relevant to this inquiry.” 

 It's been about three weeks since Turing Pharmaceuticals CEO Martin Shkreli announced he'd lower the price of his drug Daraprim. 
 
 And so far, that hasn't happened. So we called Shkreli up to learn a little more about what the company's been up to since they came under fire for jacking up their drug price from $13.50 to $750. What he said didn't assure us that a change in price would come any time soon. 
 
 "I said that it would take a long amount of time to figure out how and when to lower the price," Shkreli said, in reference to his interview with ABC News when he first announced he'd cut the cost of Daraprim in response to public outcry over the hike. 
 
 Shkreli said his company, Turing Pharmaceuticals, wants to reevaluate is how much of a demand there is for Daraprim before they lower to price. The drug is currently used to treat malaria and toxoplasmosis, an infection that's extrememly harmful for people with weakened immune systems such as people with AIDS and cancer. 
 
 "Until we figure out demand, we won’t lower the price." he said. "We have to find a safe price to lower it to." 
 
 And once Turing settles on a lower price, it might not be as low as some are calling for. It likely won't be anywhere near what the original price was before the hike, Shkreli said. 
 
 Turing Pharmaceutical is not the only company that has jacked up the price of an off-patent drug: Pharma giants Pfizer, Merck, and Valeant have all come under fire for similar stunts. 
 
 "There have been hundreds of companies that have raised [their drug prices] higher, and they’re not rolling back their prices, so why should we?" 

 These crawls are part of an effort to archive pages as they are created and archive the pages that they refer to. That way, as the pages that are referenced are changed or taken from the web, a link to the version that was live when the page was written will be preserved.Then the Internet Archive hopes that references to these archived pages will be put in place of a link that would be otherwise be broken, or a companion link to allow people to see what was originally intended by a page's authors.The goal is to fix all broken links on the web . Crawls of supported "No More 404" sites.
– As of a week ago, pharmaceuticals purveyor Martin Shkreli hadn't kept his promise to lower the cost of a toxoplasmosis drug after outcry over its 5,000% price hike over the summer. Nothing much has changed since—except now the Turing Pharmaceuticals CEO is explaining why Daraprim is still boasting exorbitant prices. "I said that it would take a long amount of time to figure out how and when to lower the price," Shkreli tells Business Insider, ostensibly referencing what he told ABC News last month about lowering the price (though he didn't appear to mention any timeframe). What's holding things up, per Shkreli: the assessment process to find a pricing/demand sweet spot to bring the price per pill down from the current $750. "Until we figure out demand, we won't lower the price," he tells BI. "We have to find a safe price to lower it to." Shkreli does add, however, that the new price won't be close to the original $13.50 per pill. He also takes umbrage at getting flak for doing what other companies, such as Pfizer and Merck, do. "There have been hundreds of companies that have raised [their drug prices] higher, and they're not rolling back their prices, so why should we?" Shkreli points out. Meanwhile, New York's AG has started an inquiry into Turing, also involving whether the company violated antitrust laws by restricting Daraprim distribution to thwart generic competitors, the New York Times reports. By significantly cutting where competitors can pick up Daraprim, Turing can ensure they have a hard time testing those samples to produce an alternative drug, the paper explains. A letter from the AG's office, seen by the Times and sent to Turing on Monday, tells the company to get in touch and to "retain all documents that are potentially relevant to this inquiry." (Some think we should thank Shkreli.)